Urologicum Duisburg

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Prostate cancer16 trials
• Bladder cancer6 trials
• Insomnia1 trial

Phase

• Phase 315 trials
• Phase 25 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting11 trials
• Recruiting8 trials
• Completed2 trials
• Not yet recruiting2 trials

Lead sponsor

• AstraZeneca5 trials
• Janssen Research & Development, LLC4 trials
• Merck Sharp & Dohme LLC2 trials
• AstraZeneca AB1 trial
• Bayer1 trial
• and 10 more

Running trials

• Recruiting

  A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.

  2025-525030-57-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).

  2025-523672-23-00· Phase 2· UroTrials GmbH· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT)

  2025-521051-23-00· Phase 2· Universitaet Muenster· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06764485· Phase 3· Celgene· Source

• Recruiting

  A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

  NCT05676203· Phase 3· Jena University Hospital· Source

• Active, not recruiting

  A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

  NCT05794906· Phase 3· Bayer· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  NCT04752722· Phase 1/2· enGene, Inc.· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

  NCT04640623· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

  NCT04295447· Phase 2· Universität Münster· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Pfizer· Source

• Active, not recruiting

  Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

  NCT04114825· Phase 2· RhoVac APS· Source

• Active, not recruiting

  Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

  NCT03528694· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer8 recruiting
• Bladder cancer2 recruiting

Closed trials

• Completed

  A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

  NCT05901649· Janssen-Cilag Ltd.· Source

• Completed

  A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

  NCT05597020· Phase 4· Idorsia Pharmaceuticals Ltd.· Source